This trial is suspended!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Type I Gaucher Disease
and you are
over 16
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.

Provided treatments

  • Drug: Ambroxol

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01463215. The sponsor of the trial is Exsar Corporation and it is looking for 20 volunteers for the current phase.
Official trial title:
An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease